Adicet Bio, Inc. (LON: 0HX7)
London
· Delayed Price · Currency is GBP · Price in USD
0.908
+0.001 (0.14%)
Jan 23, 2025, 3:11 PM BST
Adicet Bio Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
143
Market Cap
61.42M GBP
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Adicet Bio News
- 14 days ago - Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - Business Wire
- 22 days ago - Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Business Wire
- 5 weeks ago - Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer - Business Wire
- 2 months ago - Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Business Wire
- 2 months ago - Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases - Business Wire
- 2 months ago - Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 - Business Wire
- 2 months ago - Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates - Business Wire